Use of antithrombin III in critical patients

ObjectiveTo evaluate the effect of the AT III concentrates upon the clinical evolution and hemostatic parameters.DesignProspective, open, randomized trial.Patients and participantsSeptic and multiple trauma patients admitted to our Intensive Care Unit.SettingLevels of AT III below 70% were used as criteria to choose 36 patients, 20 of whom received treatment with AT III and 16 did not.InterventionsAT III concentrates were administered at an initial dose of 60 U/kg followed by 10 U/kg every six hours.ResultsThe administration of AT III neither contributes to alterations in haemostasis, nor the clinical evolution (evaluated according to Apache II score).ConclusionsThe results suggest that the administration of AT III concentrates to critical patients with acquired low levels, but without manifest DIC, may not be justified; although further studies on a larger population are required to establish definite conclussions.

[1]  T. Terao,et al.  Clinical evaluation of antithrombin III concentrate (BI 6.013) for disseminated intravascular coagulation in obstetrics. Well-controlled multicenter trial. , 1987, Gynecologic and obstetric investigation.

[2]  E. Frei,et al.  Plasma Fibronectin and Associated Variables in Surgical Intensive Care Patients , 1983, Annals of surgery.

[3]  R. Jordan,et al.  Antithrombin-III prevents the lethal effects of Escherichia coli infusion in baboons. , 1988, Circulatory shock.

[4]  W. L. Ray,et al.  Changes in the blood coagulation system associated with septicemia. , 1968, The New England journal of medicine.

[5]  R. Seitz,et al.  The disturbance of hemostasis in septic shock: role of neutrophil elastase and thrombin, effects of antithrombin III and plasma substitution * , 1989, European journal of haematology.

[6]  C. Chopin,et al.  Meningococcemia and purpura fulminans in adults: acute deficiencies of proteins C and S and early treatment with antithrombin III concentrates , 2007, Intensive Care Medicine.

[7]  T. Clemmer,et al.  A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. , 1987, The New England journal of medicine.

[8]  R. Bick,et al.  Antithrombin III patterns in disseminated intravascular coagulation. , 1980, American journal of clinical pathology.

[9]  R. S. Schifreen,et al.  A quantitative automated immunoassay for fibrinogen/fibrin degradation products. , 1985, Clinical chemistry.

[10]  M. Blombäck,et al.  Antithrombin III concentrate as adjuvant in DIC treatment. A pilot study in 9 severely ill patients. , 1984, Thrombosis research.

[11]  V. Faber,et al.  Disseminated intravascular coagulation, antithrombin III, and complement in meningococcal infections. , 2009, Acta medica Scandinavica.

[12]  M. Hellgren,et al.  Blood coagulation and fibrinolytic factors and their inhibitors in critically ill patients , 2004, Intensive Care Medicine.

[13]  L. T. Mann,et al.  Antithrombin III: Protection against Death after Injection of Thromboplastin , 1969, Science.

[14]  P. Blatt,et al.  ANTITHROMBIN-III TRANSFUSION IN DISSEMINATED INTRAVASCULAR COAGULATION , 1978, The Lancet.

[15]  C. Chopin,et al.  Meningococcemia and purpura fulminans in adults: Acute deficiencies of proteins C and S and early treatment with antithrombin III concentrates , 2005, Intensive Care Medicine.

[16]  R. Wilson,et al.  Antithrombin, prekallikrein, and fibronectin levels in surgical patients. , 1986, Archives of surgery.

[17]  M. Jochum,et al.  Released granulocytic elastase: an indicator of pathobiochemical alterations in septicemia after abdominal surgery. , 1985, Surgery.

[18]  G. Müller‐Berghaus,et al.  Normal antithrombin-III activity and concentration in experimental disseminated intravascular coagulation. , 1985, Scandinavian journal of clinical and laboratory investigation. Supplementum.

[19]  E. Mammen,et al.  Human Antithrombin Concentrates and Experimental Disseminated Intravascular Coagulation , 1985, Seminars in thrombosis and hemostasis.

[20]  R. Bick.  Clinical Relevance of Antithrombin III , 1982, Seminars in thrombosis and hemostasis.

[21]  J. L. Gall,et al.  APACHE II--a severity of disease classification system. , 1986, Critical care medicine.

[22]  J. Philippé,et al.  Fibrinolysis and Coagulation in Patients with Infectious Disease and Sepsis , 1991, Thrombosis and Haemostasis.

[23]  H. Stannigel,et al.  Anticoagulant therapy by continuous heparin-abtithrombin III infusion in newborns with disseminated intravascular coagulation , 1985, European Journal of Pediatrics.

[24]  T. Emerson,et al.  Efficacy of antithrombin III supplementation in animal models of fulminant Escherichia coli endotoxemia or bacteremia. , 1989, American Journal of Medicine.

[25]  J. T. ten Cate,et al.  Antithrombin III deficiency in surgical intensive care patients. , 1981, Thrombosis Research.

[26]  H. Bergmann,et al.  Substitution of antithrombin III in shock and DIC: a randomized study. , 1985, Thrombosis research.

[27]  J. Kilpatrick,et al.  Heparin promotes the inactivation of antithrombin by neutrophil elastase. , 1987, Science.

[28]  H. Büller,et al.  Antithrombin III Infusion in Patients Undergoing Peritoneovenous Shunt Operation: Failure in the Prevention of Disseminated Intravascular Coagulation , 1983, Thrombosis and Haemostasis.

[29]  T. Abe,et al.  Antithrombin III concentrates for treatment of disseminated intravascular coagulation in children. , 1985, The American journal of pediatric hematology/oncology.

[30]  D. Triantaphyllopoulos.  Effects of Human Antithrombin III on Mortality and Blood Coagulation Induced in Rabbits by Endotoxin , 1984, Thrombosis and Haemostasis.

[31]  J. Lewis,et al.  Disseminated Intravascular Coagulation , 1980, Thrombosis and Haemostasis.

[32]  A. Clauss,et al.  Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens , 1957 .

[33]  Y. Sakata,et al.  Treatment of DIC with antithrombin III concentrates. , 1983, Bibliotheca haematologica.

[34]  L. Díaz-Flores,et al.  [Disseminated intravascular coagulation]. , 1977, Actas dermo-sifiliograficas.

[35]  H. Büller,et al.  Acquired antithrombin III deficiency: laboratory diagnosis, incidence, clinical implications, and treatment with antithrombin III concentrate. , 1989, The American journal of medicine.